RENEURON (LSE:RENE)

3.0100
Today's low: 2.8700
Sell RENE
3.1900
Today's high: 3.2500
Buy RENE
Last trade:
3.1000
Change:
 0.0250 (0.81%)
Volume:
1,775,665
Delayed price:
16:35:22
SETS
GBX

RENEURON (RENE.L, LSE, LSE:RENE)

RENE Share Performance More

52 week high4.3000 13-08-2013
52 week low2.0200 18-06-2013
52 week change 0.2750 (9.82%)
4 week volume34,188,415 22-03-2014

Latest newsMore

Signs Lease to New Facility in Wales

RNS Number : 8085E ReNeuron Group plc 15 April 2014 15 April 2014 AIM: RENE ReNeuron signs agreement to lease a new RD, manufacturing and headquarters facility in South Wales Guildford, UK, 15 April 2014: ReNeuron Groupplc (the Company) (AIM: RENE.L), the leading UK-based stem cell therapy company, is pleased to announce that it has signed an agreement with the Welsh Government to lease a landmark building at Pencoed Technology ...

ReNeuron gets approvals for two new clinical trials

ReNeuron Group, a UK-based stem cell therapy company, has received final UK regulatory and ethical approvals to commence two new clinical trials.

UK Clinical Trial Approvals

RNS Number : 2923D ReNeuron Group plc 27 March 2014 27 March 2014 AIM: RENE ReNeuron receives UK regulatory approvals for Phase II clinical trial in stroke and Phase I clinical trial in critical limb ischaemia Guildford, UK, 27 March 2014: ReNeuron Groupplc (the Company) (AIM: RENE.L), a leading UK-based stem cell therapy company, is pleased to announce that it has received final UK regulatory and ethical approvals to commence two ...

Block Listing Six Monthly Review

RNS Number : 4527C ReNeuron Group plc 17 March 2014 17 March 2014 AIM: RENE ReNeuron Group plc Block Listing Six Monthly Review Name: ReNeuron Group plc Name of Scheme: Share-based payment agreements Period of Return: From 1 June 2011 to 14 March 2014 Balance of unalloted securities under scheme(s) from previous return: 1,645,786 Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if ...

ReNeuron welcomes new health initiative

ReNeuron Group (AIM: RENE.L), a UK-based stem cell therapy company, has welcomed todays announcement from the UK Government Department of Health of the launch of the Early Access to Medicines Scheme (EAMS). The scheme is intended to encourage the early uptake of novel therapies, thereby promoting investment in medical research in the UK and strengthening its science, research and drug development industry.

Support for Early Access to Medicines Scheme

RNS Number : 3571C ReNeuron Group plc 14 March 2014 14 March 2014 AIM: RENE ReNeuron welcomes launch of UK Government Early Access to Medicines Scheme Guildford, UK, 14 March 2014: ReNeuron Groupplc (the Company) (AIM: RENE.L), a leading UK-based stem cell therapy company, welcomes todays announcement from the UK Government Department of Health of the launch of the Early Access to Medicines Scheme (EAMS). The scheme is intended to ...